Preferences for Certainty Versus Access When Evaluating New Cancer Drugs. A Discrete Choice Experiment.

London School of Economics and Political Science

Status: Completed

Conditions: Cancer

Treatments: Other: Discrete Choice Experiment (DCE)

Study type: Observational

Funder types: Other

Identifiers

NCT05936632

213621

Details and patient eligibility

About

To provide timely access to new treatments, some eligible drugs can be approved despite uncertainty surrounding the level of clinical benefit they offer patients.

It is not currently known if (and under which circumstances) people would prefer to wait to access some new drugs in exchange for greater certainty surrounding their clinical benefit.

This study aims to elicit the preferences of people in the US with experience of cancer for wait times and clinical uncertainty of new drugs.

To elicit this information, in a survey format, respondents will be presented with a hypothetical scenario and asked to state their preferences for new treatments, each with different attributes.

Enrollment: 998 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Individuals previously or currently diagnosed with any type of cancer.
• Individuals with immediate family members previously or currently diagnosed with any type of cancer.

Exclusion criteria

• Individuals without previous or current diagnosis with any type of cancer (themselves or immediate family members).